RPRX Royalty Pharma plc - Class A

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY. The company has class B common shares outstanding that are privately held.

$39.78  -1.56 (-3.77%)
As of 11/30/2021 15:59:57 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  United Kingdom
IPO date:  12/31/1997
Outstanding shares:  429,511,014
Average volume:  2,551,754
Market cap:   $17,992,216,376
Current dividend yield:  1.61%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    G7709Q104
ISIN:        GB00BMVP7Y09
Sedol:      BMVP7Y0
Valuation   (See tab for details)
PE ratio:   22.68
PB ratio:   3.06
PS ratio:   7.87
Return on equity:   13.51%
Net income %:   34.25%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy